



Hydralazine 20 mg/mL x 1 mL Injectable

The issue: Hydralazine 20 mg/mL x 1 mL injectable is a single source item from Sterimax who has indicated the drug is in short supply with intermittent availability.

NH stock status: NH has approximately six weeks of inventory and we anticipate insufficient stock if supply does not strengthen.

Practice Implications:

- Clinicians should be aware of this potential shortage.
- Clinicians should use therapeutic alternatives where possible to conserve existing hydralazine stock for high priority indications and locations:
 - High priority indications include the acute management of [severe hypertension in pregnancy](#) that is non-responsive to IV labetalol.
 - High priority patient care areas include the Emergency Department and Obstetrics/Maternity.
- Clinicians should step down to oral anti-hypertensive therapy as soon as clinically appropriate.

Potential Alternatives (IV only)*: Use parenteral therapy options where appropriate and refer to the [NH Parenteral Drug Administration Manual](#) for information on intravenous drug administration.

- Labetalol injection
- Esmolol injection
- Enalaprilat injection
- Nitroglycerin injection
- Nitroprusside injection

November 26, 2021 For the information of physicians, nurses, and pharmacists. PLEASE POST	Drug Shortage	✓	For further information contact: Medication Use Management Pharmacists mumpharmacist@northernhealth.ca
	Drug Discontinuation		
	Medication Change		
	Best Practice		

*Alternatives are provided for clinician information and may not be appropriate for all clinical situations. The information provided does not replace clinical judgment.